MedTrace Logo

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

NCT04364399 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 920

Last updated 2021-08-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (MMRV).

Conditions

Interventions

BIOLOGICAL

Mumps vaccine

One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50

BIOLOGICAL

measles, mumps and rubella combined vaccine, live

One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50

Sponsors & Collaborators

  • Sinovac (Dalian) Vaccine Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lirong Huang, Bachelor · Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Months
Max Age
12 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2020-11-18
Completion
2021-04-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04364399 on ClinicalTrials.gov